AADI vs. AKYA, ALLK, GTHX, RIGL, GALT, ATOS, SGMT, RZLT, ALIM, and PRQR
Should you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include Akoya Biosciences (AKYA), Allakos (ALLK), G1 Therapeutics (GTHX), Rigel Pharmaceuticals (RIGL), Galectin Therapeutics (GALT), Atossa Therapeutics (ATOS), Sagimet Biosciences (SGMT), Rezolute (RZLT), Alimera Sciences (ALIM), and ProQR Therapeutics (PRQR). These companies are all part of the "medical" sector.
Aadi Bioscience (NASDAQ:AADI) and Akoya Biosciences (NASDAQ:AKYA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.
Aadi Bioscience has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Akoya Biosciences has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.
Akoya Biosciences has a net margin of -72.68% compared to Aadi Bioscience's net margin of -288.72%. Aadi Bioscience's return on equity of -61.83% beat Akoya Biosciences' return on equity.
Akoya Biosciences has higher revenue and earnings than Aadi Bioscience. Akoya Biosciences is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
Akoya Biosciences received 17 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 60.87% of users gave Akoya Biosciences an outperform vote while only 47.83% of users gave Aadi Bioscience an outperform vote.
Aadi Bioscience currently has a consensus price target of $20.50, indicating a potential upside of 1,038.89%. Akoya Biosciences has a consensus price target of $7.79, indicating a potential upside of 262.13%. Given Aadi Bioscience's higher probable upside, equities analysts plainly believe Aadi Bioscience is more favorable than Akoya Biosciences.
52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 79.4% of Akoya Biosciences shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 7.3% of Akoya Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Aadi Bioscience and Aadi Bioscience both had 4 articles in the media. Akoya Biosciences' average media sentiment score of 0.84 beat Aadi Bioscience's score of 0.53 indicating that Akoya Biosciences is being referred to more favorably in the news media.
Summary
Akoya Biosciences beats Aadi Bioscience on 12 of the 17 factors compared between the two stocks.
Get Aadi Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Aadi Bioscience Competitors List
Related Companies and Tools